
|Articles|December 1, 2004
Medicare revenue for urologists will drop 14% in 2005
Washington--The Centers for Medicare & Medicaid Services has published its final rule implementing the 2005 Medicare fee schedule, and it's not good news for urologists-especially those who administer cancer drugs in their offices.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5











